AJOVista LLC Takes $77,000 Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

AJOVista LLC purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) in the 4th quarter, HoldingsChannel reports. The institutional investor purchased 17,018 shares of the biotechnology company’s stock, valued at approximately $77,000.

Other institutional investors also recently added to or reduced their stakes in the company. GSA Capital Partners LLP lifted its position in ADMA Biologics by 87.7% during the third quarter. GSA Capital Partners LLP now owns 242,284 shares of the biotechnology company’s stock valued at $867,000 after acquiring an additional 113,184 shares during the last quarter. Qube Research & Technologies Ltd grew its position in ADMA Biologics by 22.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,204,648 shares of the biotechnology company’s stock worth $4,313,000 after purchasing an additional 224,696 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of ADMA Biologics by 20.8% during the third quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock valued at $17,514,000 after buying an additional 840,761 shares during the last quarter. Aigen Investment Management LP acquired a new position in shares of ADMA Biologics in the third quarter valued at about $140,000. Finally, SG Americas Securities LLC raised its position in ADMA Biologics by 417.3% during the 4th quarter. SG Americas Securities LLC now owns 93,236 shares of the biotechnology company’s stock worth $421,000 after buying an additional 75,213 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

ADMA traded up $0.07 during trading on Friday, reaching $6.81. The company’s stock had a trading volume of 2,985,668 shares, compared to its average volume of 2,092,217. The firm has a fifty day simple moving average of $6.21 and a two-hundred day simple moving average of $5.00. ADMA Biologics, Inc. has a 1 year low of $3.06 and a 1 year high of $6.81. The company has a current ratio of 5.16, a quick ratio of 1.69 and a debt-to-equity ratio of 1.04.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. ADMA Biologics had a positive return on equity of 0.49% and a negative net margin of 10.94%. The business had revenue of $73.90 million during the quarter, compared to the consensus estimate of $73.50 million. As a group, analysts predict that ADMA Biologics, Inc. will post 0.3 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Mizuho lifted their price target on ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, March 1st. HC Wainwright restated a “buy” rating and set a $7.50 price target (up previously from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. Finally, Cantor Fitzgerald raised their target price on ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, ADMA Biologics presently has a consensus rating of “Buy” and a consensus target price of $7.88.

Insider Activity

In other ADMA Biologics news, Director Steve Elms sold 183,008 shares of ADMA Biologics stock in a transaction on Friday, March 15th. The stock was sold at an average price of $6.01, for a total value of $1,099,878.08. Following the sale, the director now owns 2,577,387 shares in the company, valued at $15,490,095.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 639,895 shares of company stock valued at $3,927,169. 6.00% of the stock is currently owned by company insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.